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Bone loss with aging results from attenuated and unbalanced bone turnover that has been associated with a decreased number of
bone forming osteoblasts, an increased number of bone resorbing osteoclasts, and an increased number of adipocytes (fat cells)
in the bone marrow. Osteoblasts and adipocytes are derived from marrow mesenchymal stroma/stem cells (MSC). The milieu of
intracellular and extracellular signals that controls MSC lineage allocation is diverse. The adipocyte-speciﬁc transcription factor
peroxisome proliferator-activated receptor-gamma (PPAR-γ)a c t sa sac r i t i c a lp o s i t i v er e g u l a t o ro fm a r r o wa d i p o c y t ef o r m a t i o n
and as a negative regulator of osteoblast development. In vivo, increased PPAR-γ activity leads to bone loss, similar to the bone loss
observed with aging, whereas decreased PPAR-γ activity results in increased bone mass. Emerging evidence suggests that the pro-
adipocytic and the anti-osteoblastic properties of PPAR-γ are ligand-selective, suggesting the existence of multiple mechanisms by
which PPAR-γ controls bone mass and fat mass in bone.
Copyright © 2006 B. Lecka-Czernik and L. J. Suva. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
INTRODUCTION
The two-faced ancient Roman god Janus, represents the in-
separable relationship between opposites. The nuclear recep-
tor and transcription factor PPAR-γ has many “faces” in re-
gard to its activities, but its proadipocytic and antiosteoblas-
tic activities in bone closely resemble the two inseparable
faces of Janus.
The decreased rate of bone formation and the number of
osteoblasts that occurs with aging correlate inversely with an
increase in the fat content and a number of adipocytes in the
bone marrow [1]. The apparent inverse relationship between
osteoblast and adipocyte diﬀerentiations and their shared
mesenchymal progenitor origin led to the formulation of the
hypothesis that binds these two phenotypes and makes them
inseparable[2,3].Accordingtothesharedprecursorhypoth-
esis, an increase in adipocyte diﬀerentiation occurs at the
expense of osteoblast diﬀerentiation, and vice versa. How-
ever, in some circumstances, adipocytic and osteoblastic dif-
ferentiation may occur independently [4, 5], suggesting ei-
ther an existence in adult marrow of separate pools of pro-
genitorcellsrespondingtoproosteoblasticandproadipocytic
stimuli diﬀerently and/or separate regulatory mechanisms
of both osteoblast and adipocyte diﬀerentiations. This re-
view summarizes the existing evidence supporting either the
“simultaneous” scenario or the “independent” scenario. We
cite examples, in which the proadipocytic and antiosteoblas-
tic activities of PPAR-γ can be modulated either simultane-
ously or independently using ligands of diﬀerent chemical
structures. We also summarize the evidence indicating that
PPAR-γ is an important regulator of bone homeostasis and
marrow mesenchymal stem cell (MSC) diﬀerentiation.
Osteoblasts, bone-forming cells, and adipocytes, fat cells,
are derived from a common marrow MSC compartment,
which also serves as a source of progenitors for ﬁbroblasts,
muscle, and cartilage cells, and functions as hematopoiesis-
supportingstroma[6,7].Thec ommitmentofMSCst o war ds
eithertheadipocyteorosteoblastlineageoccursbyastochas-
tic mechanism [8], in which lineage-speciﬁc transcription
factors, such as Runx2, Dlx5, and Osterix for osteoblasts and
PPAR-γ2 and C/EBPs for adipocytes, are activated (Figure 1)
[9].
Aging is associated with changes in the status of MSCs
and in the milieu of intrinsic and extrinsic signals that deter-
mine the diﬀerentiation of MSCs towards osteoblasts and/or
adipocytes [1, 10–12]. These changes modulate the contin-
uing dialog between phenotype-speciﬁc transcription fac-
tors and signals from the microenvironment that collec-
tively determines MSC lineage allocation. With aging, the
status of MSCs changes with respect to their diﬀerentiation2 PPAR Research
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Figure 1: Schematic representation of bone cell development.
potential, such that commitment to the osteoblast lineage
decreases, whereas commitment to the adipocyte lineage in-
creases [1, 10]. These changes in cellular diﬀerentiation are
reﬂected in the expression proﬁle of phenotype-speciﬁc gene
markers in undiﬀerentiated MSCs. The expression of the
osteoblast-speciﬁc transcription factors, Runx2 and Dlx5,
and osteoblast markers, collagen and osteocalcin, is de-
creased, whereas expression of the adipocyte-speciﬁc tran-
scription factor PPAR-γ2 and a gene marker of adipocyte
phenotype, fatty acid-binding protein 4 (FABP4), is in-
creased [10]. Aging also results in alterations in the bone
marrow microenvironment. MSC support for osteoclastoge-
nesisisenhancedduetotheincreasedproductioninthemar-
row of macrophage colony-stimulating factor (M-CSF) and
RANKL, two proosteoclastic cytokines required for physio-
logicalboner esorption[13–16].Moreover,bonemarrowde-
rived from old mice produces unknown PPAR-γ activator(s)
that stimulates adipocyte diﬀerentiation and suppresses os-
teoblast diﬀerentiation [10]. Interestingly, in humans os-
teoblast diﬀerentiation can be aﬀected by either a presence of
mature marrow adipocytes [17], polyunsaturated fatty acids,
which are natural ligands for PPAR-γ [18], or serum derived
from older women [12].
PPAR-γ REGULATES BONE MASS
PPAR-γ nuclear receptor is an essential regulator of lipid,
glucose, and insulin metabolism [19]. The receptor is ex-
pressedinmiceandhumansastwodiﬀerentisoforms,PPAR-
γ1 and PPAR-γ2, due to alternative promoter usage and al-
ternative splicing [20–22]. PPAR-γ2d i ﬀers from PPAR-γ1
by 30 additional amino acids on its N-terminus. PPAR-γ1
is expressed in a variety of cell types, including osteoblasts,
whereas PPAR-γ2 expression is restricted to adipocytes, in-
cluding marrow adipocytes, and is essential for diﬀeren-
tiation and maintenance of their phenotype and function
[9, 23]. PPAR-γ belongs to the family of nuclear receptor
transcription factors, and its activation requires heterodimer
formationwithanothernuclearreceptor,retinoid X receptor
(RXR), and binding of a speciﬁc ligand. Natural ligands for
PPAR-γ comprise polyunsaturated fatty acids and metabo-
lites of prostaglandin J2, whereas synthetic ligands include
the antidiabetic thiazolidinediones (TZDs) [24].
An important role of PPAR-γ in the maintenance of bone
homeostasis has been demonstrated in several animal mod-
e l so fb o n ea c c r u a l[ 25, 26]o rb o n el o s s[ 27–30], regulated
by the status of PPAR-γ activity. Decreased PPAR-γ activ-
ity in PPAR-γ-haploinsuﬃcient mice or in mice carrying a
hypomorphic mutation in the PPAR-γ gene locus led to in-
creased bone mass, due to increased osteoblastogenesis from
bone marrow progenitors, but not due to eﬀects on mature
osteoblast activity or cells of the osteoclast lineage [25, 26].
Moreover,age-relatedosteopeniadidnotdevelopinPPAR-γ-
haploinsuﬃcientmice[25].Incontrast,activationofPPAR-γ
via the administration of rosiglitazone, an antidiabetic TZD,
to rodents resulted in signiﬁcant decreases in bone min-
eral density (BMD), bone volume, and changes in bone mi-
croarchitecture [27–30] .T h eb o n el o s so b s e r v e dw a sa s s o -
ciated with the expected reciprocal changes in the structure
and function of bone marrow; a decreased number of os-
teoblasts and an increased number of adipocytes [27, 30].
Indeed, we had previously demonstrated in U-33/γ2 cells, a
model of murine marrow mesenchymal cell diﬀerentiation,
that activation of the PPAR-γ2 isoform by rosiglitazone con-
verted cells of the osteoblast lineage to terminally diﬀerenti-
ated adipocytes irreversibly suppressing the osteoblast phe-
notype via the inhibition of osteoblast-speciﬁc gene expres-
sion [9].
While the antiosteoblastic eﬀect of PPAR-γ2o no s -
teoblast diﬀerentiation is well established, its eﬀect on os-
teoclast development is less clear. In vitro, PPAR-γ activa-
tion in osteoclast precursor cells inhibits their diﬀerentia-
tion [31, 32], whereas activation of PPAR-γ in cells of mes-
enchymal lineage increases their support to osteoclastogene-
sis[33].Invivo,andincontrasttootheranimalmodels,bone
loss due to rosiglitazone administration to ovariectomized
rats resulted from increased bone resorption, but not de-
creased bone formation [28]. These results indicate that at
least in some circumstances, bone loss due to PPAR-γ activa-
tion may involve increased bone resorption.
Since TZDs have only been approved for clinical use in
the treatment of type II diabetes since 1999, their eﬀects on
human bone are just emerging. Early observations indicated
that the 4-week administration of troglitazone to patients
with poorly controlled type II diabetes who exhibited high
bone turnover resulted in a signiﬁcant decrease in metabolic
bone markers, such as urinary deoxypyridinoline, urinary
type I collagen C-terminal telopeptide, and serum bone-type
alkaline phosphatase [34]. Recent analysis of data from the
Health, Aging, and Body Composition cohort indicate that
TZD use for more than 3 years results in the acceleration
of bone loss, at approximately 1% per year in older post-
menopausal women [35].
Emerging evidence from studies of PPAR-γ gene poly-
morphism in humans strongly suggests a role for this tran-
scription factor in the regulation of bone mass. A silent C →
T transition in exon 6, which is common to both PPAR-γB. Lecka-Czernik and L. J. Suva 3
isoforms, results in a lower bone density and a predispo-
sition to osteoporosis in postmenopausal Japanese women
[36]. The same polymorphism in a population of healthy
middle-age Korean women was associated with lower lev-
els of circulating osteoprotegerin, a negative regulator of os-
teoclast development, but no changes in bone density [37].
Another polymorphism in the STAT5B regulatory element
in the alternative promoter of the human PPAR-γ1p r o t e i n
was associated with increased height and plasma low-density
lipoprotein cholesterol concentrations in a French popula-
tion [38]. Similarly, analysis of a population from the Fram-
ingham Oﬀspring study revealed several novel polymorphic
changes in the coding region of PPAR-γ that correlated in-
dependently with bone mineral density (BMD) at diﬀerent
skeletal sites [39]. A more detailed review of the associations
between PPAR-γ genomic polymorphism and bone status
can be found in this issue [40].
As mentioned above, natural ligands of PPAR-γ include
polyunsaturated fatty acids and their oxidized derivatives,
the levels of which increase in the circulation with aging. We
showed previously that oxidized forms of linoleic acid serve
as ligands for PPAR-γ2 in marrow MSC and activate either
its proadipocytic and/or antiosteoblastic properties [4]. Ox-
idized fatty acids are generated in the enzymatic reactions
controlled by lipoxygenases. It was demonstrated that three
of them, 5-, 12-, and 15-lipoxygenases, are involved in the
regulation of bone mass in mice and human. The disruption
of either 5- or 15-lipoxygenase in mice led to increased bone
mass [41, 42], whereas in humans polymorphic changes in
the locus for 12- or 15-lipoxygenases correlated with changes
i nB M Di nn o r m a ls u b j e c t so ri np o s t m e n o p a u s a lw o m e n ,
respectively [43, 44].
Age-related osteoporosis is typiﬁed by a low serum IGF-
1 level and a particular pattern of fat redistribution [45–47].
I G F - 1s e r v e sa ni m p o r t a n tr e g u l a t o r yr o l ei nb o n ea c q u i s i -
tion and maintenance of the adult skeleton, although its role
in mesenchymal stem cell allocation towards the osteoblas-
tic and adipocytic lineages remains unclear [46, 48]. Re-
cent advances in genetic techniques to manipulate the mouse
genome have resulted in several murine models that provide
insights into the skeletal actions of IGF-1 and its potential
interaction with other bone regulatory mechanisms.
One such animal model reﬂecting the relationship of
IGF-1 with bone and fat consists of the congenic B6.C3H-
6T (6T) mouse, which is a C57BL/6J (B6) mouse that car-
ries a region of the C3H/HeJ (C3H) sixth chromosome [49].
Compared to B6, the 6T strain is characterized by low BMD,
increased marrow fat, a reduced serum IGF-1 concentration,
and reduced mRNA levels of IGF-1. Interestingly, the PPARγ
gene is within the carried-over C3H-like region. Moreover,
our recent results suggest that IGF-1 production in bone is
under the control of the PPARγ gene [50].
ROLE OF MARROW FAT AND ITS SIGNIFICANCE
FOR THE MARROW MICROENVIRONMENT
As mentioned above, the PPAR-γ transcription factor is es-
sential for both extramedullary and bone marrow fat devel-
opment [19, 25], yet bone marrow adipocyte biology and
function are not well understood. The marrow adipocyte
phenotype is similar to that of adipocytes present in white
andbrownfattissues,buttheuniquelocationofthesecellsin
bone directs their more specialized functions [3]. For years,
marrow fat was merely considered as a cellular component
of bone that served a passive role by occupying a space no
longer needed for hematopoiesis. However, recent develop-
ments suggesting that marrow fat plays an essential role as an
endocrine organ involved in lipid and glucose metabolism
place marrow fat under a new research spotlight. With ad-
vancing age, fat inﬁltrates bone marrow cavities, especially in
the long bones [51]. From the perspective of adipokine pro-
duction and glucose utilization, which is similar to white and
brown fat, it is likely that marrow fat serves a variety of en-
docrine functions.
A relatively well-characterized role of marrow adipocytes
is to support hematopoiesis by producing the necessary cy-
tokines and providing heat for hematopoietic cell devel-
opment. In addition, marrow fat may participate in lipid
metabolism by clearing and storing circulating triglycerides
and may provide a localized energy reservoir for emergency
situations aﬀecting, for example, osteogenesis (eg, bone frac-
turehealing)[3].Marrowadipocytesalsoproduceseveralcy-
tokines, but two adipokines, whose expression is under the
PPAR-γ control, leptin and adiponectin, are currently the fo-
cusofincreasedattentionaspossibleregulatorsofbonemass.
Leptin is produced by fat cells, and its primary role is the
regulation of satiety through the eﬀects on central nervous
system [52]. Leptin expression increases during a starvation
period resulting in decreases in growth, fertility, and bone
mass; its expression decreases when energy intake increases.
Leptin is thought to regulate bone mass through two alter-
native pathways: one involving a direct stimulatory eﬀect on
bone growth, when acting on bone cells through its recep-
tors; and another, which is indirect, involving a hypothala-
mic relay that suppresses bone formation, when acting on
central nervous system [52]. Thus, when acting locally on
bone, leptin increases BMD, bone mineral content (BMC),
and bone-formation rate, while it decreases the number and
the size of bone marrow adipocytes [52]. In contrast, when
injected into a hypothalamic ventricle, leptin decreases bone
mass in the spine [53]. This activity is presumably mediated
viaβ2-adrenergicreceptorssignaling,whichregulatestheex-
pression of RANKL in osteoblasts [54].
Another adipokine, adiponectin, was recently discov-
ered to be an insulin-sensitizing hormone produced by fat
tissue [55]. Clinical studies implicate adiponectin as an
independent predictor of bone mass; circulating levels of
adiponectin correlate inversely with bone mass in humans
[56]. Adiponectin and its receptors, similar to leptin and
its receptors, are expressed by cells of the osteoblast lineage
[57–60]. In vitro, adiponectin inhibits adipocyte formation
andstimulatesosteoblastproliferationanddiﬀerentiationvia
the MAPK signaling pathways [59], however adiponectin-
deﬁcient or transgenic for its expression mice did not show
bone abnormalities [60]. Since adiponectin can act on bone
through either an autocrine/paracrine pathway and/or an4 PPAR Research
endocrine pathway as a hormone secreted from fat tissue,
Shinoda et al. concluded that adiponectin may have three
distinctactionsonbone:apositiveactionoflocallyproduced
adiponectin through an autocrine/paracrine pathway, a di-
rect negative eﬀect of circulating adiponectin, and a positive
indirect action of circulating adiponectin via the enhance-
ment of insulin signaling [60].
EVIDENCE FOR THE RECIPROCAL RELATIONSHIP
BETWEEN BONE LOSS AND OSTEOBLAST
AND ADIPOCYTE DEVELOPMENT
Accumulating in vivo and in vitro evidences support the hy-
pothesis that increased adipocyte formation occurs at the ex-
pense of osteoblast development. In humans, the association
between bone loss and increased marrow adiposity is visible
not only during aging, but also during conditions of skele-
tal disuse, such as microgravity or paraplegia [51, 61, 62]. In
animals, skeletal unloading results in bone loss, which is also
associated with an increase in the marrow fat compartment
[63–66].
In contrast, the lack of adipose tissue has been associ-
ated with increased bone formation. In patients with con-
genital generalized lipodystrophy, a lack of body fat is ac-
companied by skeletal abnormalities, such as increased bone
density, a thickened calvarium, and scoliosis [67, 68]. An
animal model of lipodystrophy due to a hypomorphic mu-
tation in the PPAR-γ gene exhibits both decreased marrow
fat content and increased bone mass [26]. On the other
hand, embryonic ﬁbroblasts carrying a null mutation in the
PPAR-γ gene spontaneously diﬀerentiate towards osteoblasts
and do not possess the capability to diﬀerentiate towards
adipocytes [25]. Strong evidence for a reciprocal relationship
between adipocyte formation and bone loss is provided by
studies that have examined the eﬀect of TZDs, highly spe-
ciﬁc PPAR-γ agonists, on bone and bone marrow cell diﬀer-
entiation, as described above [27–30]. In support of this evi-
dence, we have previously demonstrated in an in vitro model
of marrow mesenchymal cell diﬀerentiation (U-33/γ2 cells)
that activation of the PPAR-γ2 isoform by rosiglitazone con-
verted cells of the osteoblast lineage to terminally diﬀeren-
tiated adipocytes and irreversibly suppressed both the os-
teoblast phenotype and osteoblast-speciﬁc gene expression
[9].
In the SAMP6 mouse model of involutional osteope-
nia associated with early senescence, low bone mass results
from a diminished ability of MSCs to diﬀerentiate towards
osteoblasts [69, 70]. Simultaneously, MSCs of SAMP6 mice
exhibit an increased commitment towards the adipocyte
lineage [71]. The impaired marrow osteogenesis is associ-
ated with a reduction in endochondral, but not periosteal,
new bone formation, which suggests a defective diﬀerenti-
ation of osteogenic progenitors present in the bone mar-
row [72]. Importantly, this defect is completely corrected
when bone marrow derived from normal nonosteopenic
mice is transplanted into irradiated SAMP6 mice [73]. Al-
logeneic bone marrow transplantation resulted in histologi-
cally normal trabecular bone and bone density and restored
circulating levels of interleukin (IL)-11, RANKL, and IL-6,
all cytokines involved in the regulation of bone remodel-
ing.
T h et e r m i n a ld i ﬀerentiation of MSC towards osteoblasts
and adipocytes results from the selective activation of spe-
ciﬁc programs of gene expression, which are controlled by
phenotype-speciﬁc transcription factors, such as Runx2 and
PPAR-γ, respectively. However, the control of expression and
the activity of these factors, and their precise role in MSC
lineage allocation, remain poorly understood. The recent
identiﬁcation of TAZ (transcriptional coactivator with PDZ-
binding motif) provides some insight into how the activ-
ity of transcriptional regulators may be controlled and sug-
gests that TAZ may act as a molecular switch in the dif-
ferentiation of MSC to osteoblasts and adipocytes [74, 75].
TAZ protein functions in the convergance of extracellular
signals from the cytoplasm to the nucleus [74], where it
binds to the large number of transcription factors includ-
ing Runx2 and PPAR-γ [76]. Binding of TAZ to Runx2
strongly coactivates Runx2-dependent gene transcription,
whilebindingtoPPAR-γ suppressesPPAR-γ-dependentgene
transcription. Interestingly, closely related to TAZ protein,
Yes-associated protein, YAP, acts as a strong repressor of
Runx2 transcriptional activity and osteoblast diﬀerentiation
in a manner that requires Src/Yes kinases activity [77]. How-
ever, its eﬀect on adipocyte diﬀerentiation and PPAR-γ ac-
tivity remains to be determined. Nevertheless, TAZ and
YAP transcriptional modulators are suggested to be func-
tionally related to β-catenin with respect to their role in
integration of extracellular, membrane, and cytoskeletal-
derived signals to inﬂuence mesenchymal stem cell fate
[74].
Recent discoveries identifying an important role for the
Wnt signaling pathway in postnatal bone accrual, by reg-
ulating osteoblast and osteoclast development, have pro-
vided major advances in our understanding of skeletal biol-
ogy [78, 79]. Wnts are soluble glycoproteins that engage re-
ceptor complexes composed of Lrp5/6 and frizzled proteins,
which induce a cascade of intracellular events that stabilize
β-catenin, facilitating its transport to nuclei where it binds
Lef1/Tcf transcription factors, and alters gene expression to
promote osteoblast expansion and function. The ﬁrst indi-
cation that Wnt signaling plays a critical role in bone for-
mation came from human studies where inactivating mu-
tations in the Wnt coreceptor LRP5 were shown to cause
osteoporosis [80]. In contrast, gain of function mutations
in LRP5 that increase Wnt signaling results in higher bone
density in humans and mice [81, 82]. The Wnt pathway has
also been implicated in the regulation of lineage allocation
of MSC. Animals that express Wnt10b under the control
of FABP4 in marrow are characterized by high bone mass,
whichismaintainedduringaging[83,84].Interestingly,Wnt
10b suppresses PPAR-γ expression and adipocyte develop-
ment [83] and vice versa, PPAR-γ2 suppresses Wnt10b ex-
pression in U-33/γ2 cells [4]. Recent ﬁndings indicate that
Wnt pathway not only regulates osteoblast development to-
wards bone-forming cells, but it also controls osteoblast sup-
port of osteoclastogenesis [85, 86].B. Lecka-Czernik and L. J. Suva 5
EVIDENCE FOR NONRECIPROCAL BONE LOSS
AND OSTEOBLASTAND ADIPOCYTE
DIFFERENTIATIONS
In some circumstances, osteoblast and adipocyte diﬀerentia-
tions may have a nonreciprocal nature. Recently, we demon-
strated that administration of the selective TZD netoglita-
zone to animals resulted in extensive accumulation of mar-
row fat, but did not aﬀect bone mass [5]. Similar ﬁndings
were reported previously by Tornvig et al [87], who demon-
strated that the administration of another TZD, troglitazone,
to apolipoprotein E-deﬁcient mice for 10 months did not af-
fect bone mass, although it increased the number of marrow
adipocytes and appeared to aﬀect the marrow hematopoietic
compartment. These data suggest that in vivo antiosteoblas-
tic and proadipocytic activities of PPAR-γ can be indepen-
dently activated by selective PPAR-γ modulators.
The nonreciprocal character of osteoblast and adipocyte
diﬀerentiations is alsosupported byseveralanimal models of
bone mass regulation that are not directly related to PPAR-γ
activity in MSCs. Mice deﬁcient in 11β-hydroxysteroid dehy-
drogenase type 1 (HSD1−/−), an enzyme that converts inac-
tive cortisone into active cortisol, exhibit normal bone for-
mation and bone loss with aging in the absence of marrow
adipocytes [88]. Conversely, overexpression of the transcrip-
tional regulator δFosB in cells of the osteoblast lineage re-
sulted in an increased number of osteoblasts and increased
bone formation, with no eﬀect on the number of marrow
adipocytes [89]. In another murine model, deletion of the
early B-cell factor gene, EBF1, results in a signiﬁcant increase
in osteoblast number and bone formation, in the face of the
marrow cavity being ﬁlled with fat [90]. In total, these data
suggest that the Janus-like osteoblast-adipocyte relationship
is more complex than ﬁrst thought and likely subject to se-
lective regulation.
DIVERGENT EFFECT OF PPAR-γ ACTIVATORS ON THE
PROADIPOCYTIC AND ANTIOSTEOBLASTIC ACIVITIES
The ligand-binding pocket of PPAR-γ is promiscuous and
binds a variety of molecules with diﬀerent aﬃnities [24].
We showed that PPAR-γ2 activation in osteoblast cells using
natural and artiﬁcial ligands with distinct pharmacophores
and binding aﬃnities resulted in a divergent activation of the
proadipocytic and antiosteoblastic activity of PPAR-γ2[ 4].
For example, using a variety of oxidized linoleic acid deriva-
tives (eg, its epoxy-, hydroxy- and dihydroxy-derivatives) we
were able to demonstrate that the proadipocytic and an-
tiosteoblastic activities of PPAR-γ2 can be separated. These
results suggested that PPAR-γ2e ﬀects on osteoblast and
adipocyte phenotypes are mediated by distinct regulatory
pathways that are diﬀerentially modulated depending on the
natureoftheligand.Moreover,theysuggestedthattheremay
be selective PPAR-γ2 modulators that have beneﬁcial activ-
ities as insulin sensitizers, without adverse eﬀects on bone.
Therefore, we have tested whether any of the available FDA-
approved antidiabetic TZDs also modulate PPAR-γ2a c t i v i -
ties diﬀerently.
Using U-33/γ2 cells, in which osteoblast and adipocyte
diﬀerentiation is under the control of constitutively ex-
pressed PPAR-γ2[ 4, 9], we compared the antiosteoblas-
tic and proadipocytic activities of troglitazone, pioglitazone,
and rosiglitazone. The proadipocytic activity was measured
as number of U-33/γ2 cells accumulating fat, and antios-
teoblastic activity was measured as the suppression of alka-
line phosphatase enzyme activity, in response to treatment
withdiﬀerent doses of tested TZD. As showed in Figure 2,U -
33/γ2 cells responded to this treatment in a dose-dependent
manner and the antiosteoblastic and proadipocytic activities
of tested TZDs correlated with their ligand binding aﬃnity
for PPAR-γ (rosiglitazone (EC50 = 0.04μM) > pioglitazone
(EC50 = 0.5μM) > troglitazone (EC50 = 0.8μM)) [24], with
the exception to troglitazone, which appeared to have higher
proadipocytic activity than pioglitazone.
Next, we measured the eﬀect of TZDs on the expression
of adipocyte and osteoblast signature genes using quantita-
tive real-time PCR. We tested their eﬀect on gene expression
in U-33/γ2 cells and primary bone marrow cultures in con-
centrationsthatinducedfataccumulationin50%ofU-33/γ2
cells. As shown in Table 1, the eﬀects of tested TZDs, at doses
which were equally eﬀective for fat accumulation in U-33/γ2
cells, were similar. Although primary bone marrow cells re-
sponded to these treatments with a diﬀerent magnitude than
U-33/γ2 cells, all tested TZDs equally induced both proad-
ipocytic and antiosteoblastic properties of PPAR-γ in both
U-33/γ2 and primary bone marrow cells.
TheseeﬀectsareincontrasttotheeﬀectsofanotherTZD,
netoglitazone [5]. Netoglitazone appears to be a synthetic
PPAR-γ ligand that separates the proadipocytic and antidi-
abetic activities from the antibone activity in vivo. Netoglita-
zone administered at a dose equally eﬀective as rosiglitazone
in lowering blood glucose in a murine model of type 2 dia-
betes did not induce bone loss, aﬀect changes in bone mi-
croarchitecture, or alter bone-speciﬁc gene expression. Inter-
estingly, netoglitazone, which possesses weak proadipocytic
activities in vitro eﬀectively induced marrow adipocyte for-
mation in vivo. Regardless of the discrepancies between the
in vitro and in vivo proadipocytic eﬀects of netoglitazone,
these results indicate that it is possible to separate the pro-
adipocytic and antiosteoblastic activities of PPAR-γ in vivo.
They also suggest that in vivo, at least some of the mar-
row cells are responsive to netoglitazone and thereby me-
diating the proadipocytic activity. Interestingly, it appears
that this population of cells is not involved in production
of bone-forming osteoblasts. Collectively, these data sug-
gest that these eﬀects are modulated by the cellular environ-
ment and/or the availability of speciﬁc cofactors required for
PPAR-γ activity [91].
CONCLUSIONS
Osteoporosis, obesity, and diabetes are the most common
pathologies seen in highly industrialized countries and the
cost impact to treat these diseases is enormous and still
growing. Since PPAR-γ is positioned at the cross-roads of
the control of bone mass, energy expenditure, and glucose6 PPAR Research
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Figure 2: The eﬀect of tested glitazones on adipocyte (a) and osteoblast (b) phenotypes of U-33/γ2 cells. U-33/γ2 cells represent marrow
mesenchymal bipotential progenitor cells, which diﬀerentiation towards osteoblast and adipocyte is under the control of PPAR-γ2 transcrip-
tion factor. Cells were treated for 3 days with diﬀerent doses of tested PPAR-γ agonists and cultures were either stained for fat with Oil Red-O
or subjected to alkaline phosphatase enzyme activity assay as previously described [4].
Table 1: The eﬀects of TZDs on osteoblast and adipocyte gene markers.
Treatment Cell type PPAR-γ2 FABP4 Dlx5 Runx2 OC Coll
Rosiglitazone(a) U-33/γ24 .0(d) 2,558.00 .18 0.23 0.01 0.26
Bone marrow 74.89 4 .40 .27 0.14 0.13 0.18
Pioglitazone(b) U-33/γ22 .4 1,857.00 .15 0.21 0.01 0.19
Bone marrow 367.88 4 .00 .40 0.39 0.16 0.14
Troglitazone(c) U-33/γ22 .9 2,234.00 .14 0.19 0.01 0.18
Bone marrow 160.8 108.00 .39 0.32 0.07 0.17
TZDs concentrations: (a)1μM; (b)6μM; (c)10μM; (d) values represent fold of gene expression in cells treated with TZDs versus untreated control.
metabolism, changes in its activity, which occur either natu-
rallyduringagingorduringantidiabetictherapyusingTZDs,
may result in unwanted eﬀects on the skeleton. The attrac-
tive possibility to separate speciﬁc PPAR-γ activities may al-
low for the development of selective antidiabetic modulators
that will also be safe for the skeleton. Such a possibility en-
sures that there will be a continued discovery eﬀort to iden-
tifypharmacophoresthatwillbeofbeneﬁtforbothboneand
glucose metabolism.
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